ACmab1 / Axon Neurosci - LARVOL DELTA

[VIRTUAL] AXON Neuroscience (BIO 2021) - "AXON Neuroscience is world’s most clinically advanced biotech in the field of Alzheimer’s disease tau therapeutics with first-in-man tau vaccine AADvac1. The company has successfully completed the preclinical phase for its lead COVID-19 asset: ACmab1 (therapeutic antibodies against COVID-19). This confirmed superior characteristics of ACmab1 vs. other therapies, in terms of efficacy on new mutated variants, method of administration, as well as its significantly lower pricing potential."

Alzheimer's Disease • CNS Disorders • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases